Evidence map›Paper›PMID 34991476›Full record

ArticleBMC microbiology2022

Distribution of serotypes and antibiotic resistance of invasive Pseudomonas aeruginosa in a multi-country collection.

Shamima Nasrin, Nicolas Hegerle, Shaichi Sen, Joseph Nkeze, Sunil Sen, Jasnehta Permala-Booth, Myeongjin Choi, James Sinclair, Milagritos D Tapia, J Kristie Johnson and 17 more

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 59 citations in OpenAlex.

  1. XAB06, a glyco-humanized broad-spectrum anti-Antimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Article
  4. Intracellular barriers and receptor masking limit success of abioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Virulence and Resistance ofMicroorganisms · 2025
    Article
  11. Article
  12. Article
  13. NovelmBio · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Genomic features and fitness cost of co-existence ofFrontiers in cellular and infection microbiology · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 15 institutions in 12 countries.

Shamima NasrinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
Nicolas HegerleCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
Shaichi SenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
Joseph NkezeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
Sunil SenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
Jasnehta Permala-BoothCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
Myeongjin ChoiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
James SinclairCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
Milagritos D TapiaCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
J Kristie JohnsonDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
Samba O SowCentre pour le Développement des Vaccins, Mali, Bamako, Mali.
Joshua T ThadenDivision of Infectious Diseases, Duke University Medical Center, Durham, NC, USA.
Vance G FowlerDivision of Infectious Diseases and International Health, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Karen A KrogfeltStatens Serum Institut, Copenhagen, Denmark.
Annelie BraunerDepartment of Microbiology, Tumor and Cell Biology, Division of Clinical Microbiology, Karolinska Institutet and Karolinska University Hospital, 17176, Stockholm, Sweden.
Efthymia ProtonotariouDepartment of Microbiology, AHEPA University Hospital, Thessaloniki, Greece.
Eirini ChristakiDepartment of Medicine, AHEPA University Hospital, Thessaloniki, Greece.
Yuichiro ShindoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Andrea L KwaDepartment of Pharmacy, Singapore General Hospital, Singapore, Singapore.
Sadia ShakoorDepartments of Pathology and Pediatrics, Aga Khan University, Karachi, Pakistan.
Ashika Singh-MoodleyNational Institute for Communicable Diseases a Division of the National Health Laboratory Service, and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Olga PerovicNational Institute for Communicable Diseases a Division of the National Health Laboratory Service, and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Jan JacobsDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Octavie LunguyaDepartment of Clinical Microbiology, National Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Raphael SimonCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
Alan S Cross *Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
Sharon M Tennant *Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA. stennant@som.umaryland.edu.
University of Maryland, Baltimore · USAga Khan University · PKAHEPA University Hospital · GRCentre Pour le Développement des Vaccins-Mali · MLClinical Research Institute · USDuke Medical Center · USKarolinska University Hospital · SEKU Leuven · BENagoya University · JPNational Health Laboratory Service · ZANational University of Singapore · SGRoskilde University · DKUniversity of Cyprus · CYUniversity of Kinshasa · CDUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPseudomonas aeruginosa is an opportunistic pathogen that causes a wide range of acute and chronic infections and is frequently associated with healthcare-associated infections. Because of its ability to rapidly acquire resistance to antibiotics, P. aeruginosa infections are difficult to treat. Alternative strategies, such as a vaccine, are needed to prevent infections. We collected a total of 413 P. aeruginosa isolates from the blood and cerebrospinal fluid of patients from 10 countries located on 4 continents during 2005-2017 and characterized these isolates to inform vaccine development efforts. We determined the diversity and distribution of O antigen and flagellin types and antibiotic susceptibility of the invasive P. aeruginosa. We used an antibody-based agglutination assay and PCR for O antigen typing and PCR for flagellin typing. We determined antibiotic susceptibility using the Kirby-Bauer disk diffusion method.

resultsOf the 413 isolates, 314 (95%) were typed by an antibody-based agglutination assay or PCR (n = 99). Among the 20 serotypes of P. aeruginosa, the most common serotypes were O1, O2, O3, O4, O5, O6, O8, O9, O10 and O11; a vaccine that targets these 10 serotypes would confer protection against more than 80% of invasive P. aeruginosa infections. The most common flagellin type among 386 isolates was FlaB (41%). Resistance to aztreonam (56%) was most common, followed by levofloxacin (42%). We also found that 22% of strains were non-susceptible to meropenem and piperacillin-tazobactam. Ninety-nine (27%) of our collected isolates were resistant to multiple antibiotics. Isolates with FlaA2 flagellin were more commonly multidrug resistant (p = 0.04).

conclusionsVaccines targeting common O antigens and two flagellin antigens, FlaB and FlaA2, would offer an excellent strategy to prevent P. aeruginosa invasive infections.

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsFlagellinHumansMicrobial Sensitivity TestsO AntigensPseudomonas aeruginosaPseudomonas InfectionsSerogroupSerotypingAnti-Bacterial AgentsFlagellinO AntigensFlagellinMultidrug resistancePseudomonasSerotype

Identifiers

PMID34991476
PMCPMC8732956
OpenAlexW4206564835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.